Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180503732> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W3180503732 abstract "Topical glaucoma treatments, including multiple β-adrenergic receptor blocking agents, have often been limited by poor ocular absorption and bioavailability. Betaxolol, a selective β1-blocker, has been well studied for its pharmacokinetics and disposition after oral administration. However, limited betaxolol metabolism has been documented after topical dosage despite the growing number of immediate and sustained release, ocular treatments under investigation to improve absorption and retain efficacy. Conversely, plasma, urine and in vitro liver metabolism data has been reported for other topical glaucoma treatments, for example levobunolol. This investigation developed an ocular S9 assay combined with high-resolution mass spectrometry to investigate the role of ocular metabolism for preclinical and human subcellular fractions. Nine metabolites, eight of which were not previously reported, were characterized. Betaxolol’s active metabolite, hydroxybetaxolol, was observed in rat, rabbit and human ocular and liver S9 fractions. To date, hydroxybetaxolol concentrations in vivo or its binding affinity/selectivity have not been reported. Rabbit liver S9 fractions demonstrated extensive glucuronidation that was not observed ocular fractions. For betaxolol and levobunolol, investigated in a companion paper, the complete ocular metabolic profile could not be predicted from the liver S9 assay alone. This is the first comprehensive report of a functional, in vitro ocular metabolism assay, which demonstrates the poor prediction of ocular metabolism using liver as a surrogate model." @default.
- W3180503732 created "2021-07-19" @default.
- W3180503732 creator A5033218102 @default.
- W3180503732 creator A5051580170 @default.
- W3180503732 creator A5052481689 @default.
- W3180503732 date "2015-01-01" @default.
- W3180503732 modified "2023-09-26" @default.
- W3180503732 title "An in vitro approach to investigate ocular metabolism: Part II - Betaxolol" @default.
- W3180503732 hasPublicationYear "2015" @default.
- W3180503732 type Work @default.
- W3180503732 sameAs 3180503732 @default.
- W3180503732 citedByCount "0" @default.
- W3180503732 crossrefType "journal-article" @default.
- W3180503732 hasAuthorship W3180503732A5033218102 @default.
- W3180503732 hasAuthorship W3180503732A5051580170 @default.
- W3180503732 hasAuthorship W3180503732A5052481689 @default.
- W3180503732 hasConcept C112705442 @default.
- W3180503732 hasConcept C118487528 @default.
- W3180503732 hasConcept C150903083 @default.
- W3180503732 hasConcept C181389837 @default.
- W3180503732 hasConcept C185592680 @default.
- W3180503732 hasConcept C202751555 @default.
- W3180503732 hasConcept C207001950 @default.
- W3180503732 hasConcept C2777056448 @default.
- W3180503732 hasConcept C2777477808 @default.
- W3180503732 hasConcept C2778073030 @default.
- W3180503732 hasConcept C2778527774 @default.
- W3180503732 hasConcept C2779907587 @default.
- W3180503732 hasConcept C2779938033 @default.
- W3180503732 hasConcept C55493867 @default.
- W3180503732 hasConcept C62231903 @default.
- W3180503732 hasConcept C71924100 @default.
- W3180503732 hasConcept C86803240 @default.
- W3180503732 hasConcept C87644729 @default.
- W3180503732 hasConcept C98274493 @default.
- W3180503732 hasConceptScore W3180503732C112705442 @default.
- W3180503732 hasConceptScore W3180503732C118487528 @default.
- W3180503732 hasConceptScore W3180503732C150903083 @default.
- W3180503732 hasConceptScore W3180503732C181389837 @default.
- W3180503732 hasConceptScore W3180503732C185592680 @default.
- W3180503732 hasConceptScore W3180503732C202751555 @default.
- W3180503732 hasConceptScore W3180503732C207001950 @default.
- W3180503732 hasConceptScore W3180503732C2777056448 @default.
- W3180503732 hasConceptScore W3180503732C2777477808 @default.
- W3180503732 hasConceptScore W3180503732C2778073030 @default.
- W3180503732 hasConceptScore W3180503732C2778527774 @default.
- W3180503732 hasConceptScore W3180503732C2779907587 @default.
- W3180503732 hasConceptScore W3180503732C2779938033 @default.
- W3180503732 hasConceptScore W3180503732C55493867 @default.
- W3180503732 hasConceptScore W3180503732C62231903 @default.
- W3180503732 hasConceptScore W3180503732C71924100 @default.
- W3180503732 hasConceptScore W3180503732C86803240 @default.
- W3180503732 hasConceptScore W3180503732C87644729 @default.
- W3180503732 hasConceptScore W3180503732C98274493 @default.
- W3180503732 hasLocation W31805037321 @default.
- W3180503732 hasOpenAccess W3180503732 @default.
- W3180503732 hasPrimaryLocation W31805037321 @default.
- W3180503732 hasRelatedWork W1490977255 @default.
- W3180503732 hasRelatedWork W1968385069 @default.
- W3180503732 hasRelatedWork W1972193262 @default.
- W3180503732 hasRelatedWork W1977608782 @default.
- W3180503732 hasRelatedWork W1991696538 @default.
- W3180503732 hasRelatedWork W1999706540 @default.
- W3180503732 hasRelatedWork W2028152220 @default.
- W3180503732 hasRelatedWork W2066598121 @default.
- W3180503732 hasRelatedWork W2071125996 @default.
- W3180503732 hasRelatedWork W2118634071 @default.
- W3180503732 hasRelatedWork W2170625447 @default.
- W3180503732 hasRelatedWork W2409945660 @default.
- W3180503732 hasRelatedWork W2425773383 @default.
- W3180503732 hasRelatedWork W2530388172 @default.
- W3180503732 hasRelatedWork W2783861782 @default.
- W3180503732 hasRelatedWork W2795649454 @default.
- W3180503732 hasRelatedWork W3023377413 @default.
- W3180503732 hasRelatedWork W3038295886 @default.
- W3180503732 hasRelatedWork W51111220 @default.
- W3180503732 hasRelatedWork W1596339444 @default.
- W3180503732 isParatext "false" @default.
- W3180503732 isRetracted "false" @default.
- W3180503732 magId "3180503732" @default.
- W3180503732 workType "article" @default.